Translation

Notice:	This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

February 20, 2025
Alfresa Holdings Corporation

Notice Concerning Share Buyback, Completion of Acquisition

Alfresa Holdings Corporation hereby announces as below the results and conclusion of repurchases of shares of its common stock conducted pursuant to the provisions of article 459, paragraph 1 of the Companies Act, as well as the provisions of article 46 of the Company's Articles of Incorporation. This has concluded the Company's repurchase of its common stock authorized by the Board of Directors' meeting held on November 7, 2024.

(1)	Type of shares repurchased	Common stock
(2)	Number of shares repurchased	1,121,800 shares
(3)	Price of shares repurchased	¥2,311,393,263
(4)	Repurchase period	From Feb 1, 2025, to Feb 19, 2025 (contractual basis)
(5)	Acquisition method	Market purchases on the Tokyo Stock Exchange

(Reference)

1. Details of Matters concerning the Purchase Resolved Upon at the Board of Directors' Meeting held on November 7, 2024

(1)	Type of stock acquired	Common stock
(2)	Total number of shares that can be acquired	6,000,000 shares (maximum) (Ratio to the number of outstanding shares (excluding treasury stock): 3.2%)
(3)	Total acquisition value of shares	¥11.0 billion (maximum)
(4)	Acquisition period	From Nov 8, 2024, through May 30, 2025
(5)	Acquisition method	Market purchases on the Tokyo Stock Exchange

2. Aggregate Number of Treasury Shares Repurchased as of February 19, 2025, Based on the above Resolution

(1)	Aggregate number of shares repurchased	5,113,600 shares
(2)	Aggregate price of shares repurchased	¥10,999,857,633

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: https://www.alfresa.com/eng/